Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report)’s share price rose 6.2% during mid-day trading on Monday . The company traded as high as $16.98 and last traded at $16.98. Approximately 42,326 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 145,459 shares. The stock had previously closed at $15.99.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. Oppenheimer restated an “outperform” rating and issued a $28.00 price objective (up from $25.00) on shares of Tyra Biosciences in a research report on Monday, May 13th. Wedbush restated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, May 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a report on Wednesday, June 5th.
View Our Latest Report on Tyra Biosciences
Tyra Biosciences Price Performance
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. Analysts expect that Tyra Biosciences, Inc. will post -1.71 EPS for the current fiscal year.
Insider Activity
In other Tyra Biosciences news, COO Daniel Bensen sold 3,502 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the transaction, the chief operating officer now owns 427,981 shares in the company, valued at approximately $8,559,620. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.40% of the company’s stock.
Institutional Investors Weigh In On Tyra Biosciences
Several institutional investors have recently modified their holdings of TYRA. Kynam Capital Management LP bought a new position in shares of Tyra Biosciences during the 4th quarter valued at $4,712,000. AJOVista LLC purchased a new stake in shares of Tyra Biosciences in the 4th quarter worth $59,000. Wellington Management Group LLP grew its stake in shares of Tyra Biosciences by 18.5% during the 3rd quarter. Wellington Management Group LLP now owns 94,112 shares of the company’s stock valued at $1,296,000 after acquiring an additional 14,676 shares during the period. Exchange Traded Concepts LLC increased its holdings in Tyra Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock worth $132,000 after acquiring an additional 2,417 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Tyra Biosciences by 1,244.2% during the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after purchasing an additional 1,916 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Further Reading
- Five stocks we like better than Tyra Biosciences
- Using the MarketBeat Stock Split Calculator
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Using the MarketBeat Dividend Tax Calculator
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Golden Cross Stocks: Pattern, Examples and Charts
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.